Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $35.3 million.

  • Amicus Therapeutics' Free Cash Flow rose 25123.25% to $35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year increase of 13075.24%. This contributed to the annual value of -$37.4 million for FY2024, which is 5107.34% up from last year.
  • Amicus Therapeutics' Free Cash Flow amounted to $35.3 million in Q3 2025, which was up 25123.25% from -$28.9 million recorded in Q2 2025.
  • Amicus Therapeutics' 5-year Free Cash Flow high stood at $35.3 million for Q3 2025, and its period low was -$83.4 million during Q4 2022.
  • For the 5-year period, Amicus Therapeutics' Free Cash Flow averaged around -$25.1 million, with its median value being -$23.3 million (2024).
  • As far as peak fluctuations go, Amicus Therapeutics' Free Cash Flow plummeted by 34342.79% in 2024, and later surged by 25123.25% in 2025.
  • Over the past 5 years, Amicus Therapeutics' Free Cash Flow (Quarter) stood at -$72.3 million in 2021, then decreased by 15.46% to -$83.4 million in 2022, then skyrocketed by 102.07% to $1.7 million in 2023, then plummeted by 343.43% to -$4.2 million in 2024, then skyrocketed by 939.15% to $35.3 million in 2025.
  • Its Free Cash Flow stands at $35.3 million for Q3 2025, versus -$28.9 million for Q2 2025 and $7.5 million for Q1 2025.